The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...

Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General ...

Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist. The Food and Drug Administration (FDA) has approved Orgovyx TM (relugolix tablets; Myovant Sciences) for the ...

Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease. Phase 3 top-line results expected in 2027. LONDON, March 08, 2023 (GLOBE ...

ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study Conference call and webcast to be held on December 21 ...

On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...

What is androgen deprivation therapy? Alicia Morgans, M.D., MPH: Androgen deprivation therapy, sometimes called ADT or hormonal therapy, is a way of treating prostate cancer that is used pretty ...

BOSTON -- A treatment mainstay for prostate cancer puts men at increased risk for diabetes and cardiovascular disease, according to a large observational study published in the Sept. 20 Journal of ...